Conditions: Rheumatoid Arthritis
Keywords: Rheumatoid Arthritis Anti-interleukin-1 beta ACZ885
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 115
Healthy volunteers: no

Brief summary:
This study will assess the long-term safety and tolerability of ACZ885 in patients with rheumatoid arthritis, as well as long-term efficacy, long-term preservation and/or improvement of joint structure and bone mineral density, and long term maintenance of health-related quality of life.

Detailed description:

Arms:
arm 1: Participants received one single dose of 600 mg canakinumab via intravenous infusion on Day 1 and thereafter every 6 weeks until completion of the 54-week treatment period.

Interventions: intervention 1: Canakinumab
Intervention descriptions: intervention 1: Canakinumab

Protocol document: